DC Bead: In Vitro Characterization of a Drug-delivery Device for Transarterial Chemoembolization

Lewis, Andrew L.; Gonzalez, M. Victoria; Lloyd, Andrew W.; Hall, Brenda; Tang, Yiqing; Willis, S.; Leppard, Simon W.; Wolfenden, Laura C.; Palmer, Rosemary R.; Stratford, Peter W.

doi:10.1097/01.rvi.0000195323.46152.b3

Cited by 394 publications

(317 citation statements)

References 11 publications

Supporting

Mentioning

298

Contrasting

Unclassified

Order By: Relevance

“…In this study, LC beads used in DEB transarterial chemoembolization (TACE) are made up of a PVA monomer that has been modified with sulfonate groups [18]. When admixed with doxorubicin under optimal conditions the beads absorb predictable concentrations of the drug.…”

Section: Discussionmentioning

confidence: 99%

Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC)

Dhanasekaran

Kooby

Staley

et al. 2010

Journal of Surgical Oncology

193

149

View full text Add to dashboard Cite

Background and Objectives: Chemoembolization with doxorubicin drug eluting beads (DEB) is a novel locoregional treatment modality for unresectable hepatocellular carcinoma (HCC). Initial animal studies and clinical trials suggest that treatment with DEB may provide safer and more effective short-term outcomes than conventional chemoembolization. Current study explores long-term survival benefits. Methods: Consecutive patients who received transcatheter therapy with DEB or conventional chemoembolization as sole therapy between 1998 and 2008 were studied. Statistical analysis was performed using Kaplan-Meier estimator with log-rank testing, chi-squared, and independent t-tests. Results: Seventy-one patients were included in this study, 45 (63.4%) received therapy with DEB (group A) and 26 (36.6%) underwent conventional chemoembolization (group B). Median survival from diagnosis of HCC in groups A and B were 610 (351-868) and 284 days (4-563; P ¼ 0.03), respectively. In Okuda stage I, survival in groups A and B were 501 (421-528) and 354 days (148-560, P ¼ 0.02). In Child-Pugh classes A and B, survival in groups A and B were 641 (471-810) and 323 days (161-485, P ¼ 0.002). Median survival in patients with Cancer of Liver Italian Program (CLIP) score 3 in groups A and B were 469 (358-581) and 373 days (195-551, P ¼ 0.03). NCI CTCAEv3 Grade 5 clinical toxicity was similar. Conclusions: In our study, transcatheter therapy with DEB offers a survival advantage over conventional chemoembolization for patients with unresectable HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC)

Dhanasekaran

Kooby

Staley

et al. 2010

Journal of Surgical Oncology

193

149

View full text Add to dashboard Cite

show abstract

“…2. Drug-eluting beads TACE (DEB-TACE): In this case, cytostatic agents are coupled to beads with a defined size (theoretically a diameter of 40 -1200 μm, typically 100 -500 μm) [10] (all-in-one application). After release of the beads, this ionic bond continuously dissolves resulting in continuous release of the chemotherapeutic agent in the tumor.…”

Section: Discussionmentioning

confidence: 99%

Transarterial Chemoembolization - Status Quo in Germany

Niessen

Wiggermann

Velandia

et al. 2013

Fortschr Röntgenstr

View full text Add to dashboard Cite

Purpose: Against the background of the current preparation of the national disease management guideline for the diagnosis and treatment of hepatocellular carcinoma (HCC), the German Society for Interventional Radiology (DEGIR) launched a statewide survey in order to evaluate the current status of transarterial chemoembolization (TACE) in Germany. Materials and Methods: In April 2012 an e-mail questionnaire relating to TACE practices in patients with intermediate-stage HCC was sent to all chief physicians of interventional radiology departments in Germany that were members of DEGIR. Results: 96 questionnaires were completed and evaluated statistically. The most frequent combinations of embolic agents and cytotoxic drugs are drug-eluting beads combined with doxorubicin or epirubicin as well as lipiodol plus doxorubicin, epirubicin or cisplatin. 60?% of the interventionalists prefer superselective chemoembolization. In most cases more than one chemoembolization per patient is performed (95.5?%). The most common (77?%) time interval between two interventions ranges between one and two months. Conclusion: The results of this survey show the often stated criticism in Germany regarding the substantial differences in TACE protocols and highlight the importance of standards of practice for TACE in patients with HCC. Key Points: Citation Format:

show abstract

“…When the elution medium contained ions and phosphate-buffered saline solution, reproducible and sustained release profiles were achievable. With a drug load of 25 mg/mL bead, it has been shown that the rate of drug release from 700 -900 μm beads was slower than that from 100 -300 μm beads, with half-lives of 1,730 and 150 hours, respectively [42]. These half-life data translate to less than 1 % and 20 % of drug being released over 24 hours from the total available drug loaded on the 700 -900 μm beads and 100 -300 μm beads, respectively.…”

Section: Figure 4 Schematic Diagram Of the T-cell Apparatus (Citatiomentioning

confidence: 99%

“…Patients may receive three or four chemoembolization treatments within 6 months. It has been demonstrated that DC Bead spheres can easily be loaded with doxorubicin to a recommended level of 25 mg/mL hydrated beads [42].…”

Section: Drug Eluting Beadsmentioning

confidence: 99%